BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 3.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $48,480,000 | -21.2% | 5,955,762 | -21.9% | 4.80% | -38.3% |
Q4 2018 | $61,512,000 | +1.0% | 7,622,256 | -4.5% | 7.78% | -18.0% |
Q3 2018 | $60,874,000 | +42.1% | 7,978,275 | +6.7% | 9.49% | +59.7% |
Q2 2018 | $42,851,000 | -99.9% | 7,478,275 | 0.0% | 5.94% | +12.1% |
Q1 2018 | $35,671,000,000 | +152784.5% | 7,478,275 | +57.4% | 5.30% | +33.1% |
Q4 2017 | $23,332,000 | +171.9% | 4,751,883 | +190.2% | 3.98% | +138.5% |
Q3 2017 | $8,580,000 | +10.7% | 1,637,332 | +33.7% | 1.67% | +4.8% |
Q4 2016 | $7,754,000 | +142.5% | 1,225,000 | +69.0% | 1.59% | +95.5% |
Q3 2016 | $3,197,000 | – | 725,000 | – | 0.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |